Researchers recently identified several **NPC1 serum protein biomarkers** that may significantly improve the clinical management of Niemann-Pick disease, type C1. This rare and fatal neurodegenerative disorder stems from pathological variants in the NPC1 gene. These variants lead to a defect in lysosomal cholesterol transport, causing unesterified cholesterol to accumulate within the cells. Because the disease presents with high phenotypic heterogeneity, clinicians often encounter significant diagnostic delays. Therefore, the identification of reliable markers is essential to facilitate earlier diagnosis and monitor therapeutic responses.

The study utilized Proximal Extension Assays (PEA) to analyze relative protein expression levels in 68 serum samples from affected individuals. The team compared these to 20 age-appropriate control samples. Statistical models identified disease-specific effects while adjusting for various covariates. Consequently, the researchers found that 186 proteins increased significantly, while 286 proteins decreased. Notably, proteins such as CHI3L1, GDF15, and LGALS3BP showed prominent elevations in the serum of NPC1 patients.

Clinical Utility of NPC1 Serum Protein Biomarkers

The researchers validated several proteins using ELISA and found strong correlations with clinical severity scores. Specifically, CHI3L1 and GDF15 levels matched the Age of Neurological Onset (ANO) and the Annual Severity Increment Score (ASIS). Furthermore, these **NPC1 serum protein biomarkers** correlated well with the NPC Neurological Severity Score (NSS). This correlation suggests that these proteins can serve as objective measures of disease burden. In addition, the study found that certain protein levels moved toward normal values following miglustat treatment. This finding indicates their potential role as pharmacodynamic biomarkers for assessing therapeutic efficacy in clinical trials.

Frequently Asked Questions

What are the most significant protein biomarkers for NPC1?

The study highlighted CHI3L1 (YKL-40) and GDF15 as the most robust biomarkers. These proteins show a significant correlation with both the age of neurological onset and overall disease severity.

Can these biomarkers help in monitoring treatment response?

Yes, research indicates that certain protein levels, such as CHI3L1 and GDF15, may normalize following treatment with miglustat. This makes them valuable tools for tracking how well a patient is responding to therapy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.

References

1. Singhal K et al. Identification of serum protein biomarkers in individuals with Niemann-Pick disease, type C1. Biomark Res. 2026 May 09. doi: 10.1186/s40364-026-00927-x. PMID: 42106890.


2. Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:16. doi: 10.1186/1750-1172-5-16.


3. Patterson MC, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: An update. Mol Genet Metab. 2017;120(3):197-204. doi: 10.1016/j.ymgme.2017.01.001.

"